BridgeBio have significantly advanced its development of a new solution for amyloid heart disease, employing the investigational drug. Early trial data reveals promising improvements for those affected from a severe illness. The emphasis highlights the company’s dedication to treating critical medical needs in a heart disease space. Attruby: Bri